The goal of this pilot study is to validate the use of the combination of Lucentis
(ranibizumab) and Visudyne (verteporfin) in the treatment of choroidal neovascularization
(CNV) secondary to age-related macular degeneration (AMD) and to explore the use of a
volumetric analysis of the CNV lesion to determine disease activity, response to therapy, and
as a tool for determining the need for retreatment.